The logo of Swiss drugmaker Novartis is pictured at the company's French headquarters in Rueil-Malmaison (Reuters) -Swiss drugmaker Novartis has backed away from its pursuit of Cytokinetics, a person ...

Cytokinetics (NASDAQ:CYTK) quickly dropped 5.3% after the Novartis (NYSE:NVS) CEO declined to comment on a potential deal and said the company is focused on bolt-on acquisitions. "Our overall M&A ...

Jan 11 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab has backed away from its pursuit of Cytokinetics (CYTK.O), opens new tab, a person familiar with the matter told Reuters, and the ...

(Reuters) -Swiss drugmaker Novartis has backed away from its pursuit of Cytokinetics, a person familiar with the matter told Reuters, and the U.S. drug developer's shares were down over 21% in ...

Jan 11 (Reuters) - Novartis NOVN.S has backed away from its pursuit of Cytokinetics CYTK.O, the Wall Street Journal reported on Thursday, citing sources. Shares of Cytokinetics slumped over 25% on the ...